Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Paycor Announces Third Quarter Fiscal Year 2023 Financial Results

Published

on

<!– Name:DistributionId Value:8836407 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:8700 –> <!– Name:CustomerId Value:1105308 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:63238f51-5c5b-4e4d-afe0-554b1c8b3a56 –>

  • Q3 Total revenues of $161.5 million, an increase of 32% year-over-year, while expanding margins
  • Q3 Recurring revenue of $150.8 million, an increase of 23% year-over-year, and the sixth consecutive quarter of achieving 20%+ revenue growth
  • Raises FY’23 revenue and Adjusted operating income guidance $5 million and $3 million, respectively, year-over-year at the top end of the range

CINCINNATI , May 10, 2023 (GLOBE NEWSWIRE) — Paycor HCM, Inc. (Nasdaq: PYCR) (“Paycor”), a leading provider of human capital management (“HCM”) software, today announced financial results for the third quarter of fiscal year 2023, which ended March 31, 2023.

“Paycor posted robust 32% revenue growth year-over-year, reflecting continued strong demand for our innovative HCM suite and consistent execution of our go to market strategy as we expand nationally,” said Raul Villar, Jr., Chief Executive Officer of Paycor. “Paycor’s ability to invest in differentiated cloud technology that enables all leaders to be more effective while expanding margins for the fourth consecutive quarter demonstrates the scalability of our business model.”

“This quarter we launched powerful new analytics and automation capabilities that empower frontline leaders to drive business results. We continue to advance the platform with leading-edge capabilities, such as leveraging artificial intelligence to optimize sentiment in performance reviews and acquiring a behavioral science-based microlearning platform that will enable leaders to develop their employees more effectively.”

Third Quarter Fiscal Year 2023 Financial Highlights

  • Total revenues were $161.5 million, compared to $122.6 million for the third quarter of fiscal year 2022.
  • Operating loss was $8.0 million, compared to $23.5 million for the third quarter of fiscal year 2022.
  • Adjusted operating income* was $39.1 million, compared to $24.7 million for the third quarter of fiscal year 2022.
  • Net loss attributable to Paycor HCM was $7.3 million, compared to $16.7 million for the third quarter of fiscal year 2022.
  • Adjusted net income attributable to Paycor HCM* was $31.6 million, compared to $18.6 million for the third quarter of fiscal year 2022.

*Adjusted operating income and adjusted net income attributable to Paycor HCM are non-GAAP financial measures. Please see the discussion below under the heading “Non-GAAP Financial Measures” and the reconciliations at the end of this press release for information concerning these and other non-GAAP financial measures.

Third Quarter and Recent Business Highlights

  • Acquired Verb, a modern behavioral science-based microlearning solution to develop frontline leaders and their teams. Paycor plans to integrate Verb into its HCM platform to help organizations inspire positive, sustainable behavioral change through personalized development journeys.
  • Building on artificial intelligence-driven innovation such as Paycor Smart Sourcing and Predictive Resignation, Paycor introduced its existing natural language processing and sentiment analysis engines into Performance Reviews to provide frontline leaders real time feedback on the language used in evaluations to foster a more humanized, engaging work culture.
  • To further support frontline leaders, we deployed Industry Reports to provide quick access to important insights about their business.
  • Won six Titan Business Intelligence Awards spanning Paycor’s best-in-class Talent Management solution, Paycor Smart Sourcing, and insightful analytics that help frontline leaders optimize business decisions.

Business Outlook

Based on information as of today, May 10, 2023, Paycor is issuing the following financial guidance:

Fourth Quarter Ending June 30, 2023:

  • Total revenues in the range of $135-$137 million.
  • Adjusted operating income* in the range of $13-$14 million.

Fiscal Year Ending June 30, 2023:

  • Total revenues in the range of $548-$550 million.
  • Adjusted operating income* in the range of $80-$81 million.

*We are unable to reconcile forward-looking adjusted operating income to forward-looking loss from operations, the most closely comparable GAAP financial measure because the information needed to provide a complete reconciliation is unavailable at this time without unreasonable effort.

Conference Call Information

Paycor will host a conference call today, May 10, 2023, at 5:00 p.m. Eastern Time to discuss its financial results and guidance. To access this call, dial 1-877-407-4018 (domestic) or 1-201-689-8471 (international). The access code is 13735321. A live webcast and replay of the event will be available on the Paycor Investor Relations website at investors.paycor.com.

About Paycor

Paycor’s human capital management (HCM) platform modernizes every aspect of people management, from recruiting, onboarding, and payroll to career development and retention, but what really sets us apart is our focus on leaders. For more than 30 years, we’ve been listening to and partnering with leaders, so we know what they need; a unified HR platform, easy integration with third party apps, powerful analytics, talent development tools, and configurable technology that supports specific industry needs. That’s why more than 30,000 customers trust Paycor to help them solve problems and achieve their goals.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including statements regarding our future results of operations and financial position, our business outlook, our business strategy and plans, our objectives for future operations, and any statements of a general economic or industry specific nature, are forward-looking statements. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Words such as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely,” “outlook,” “potential,” “targets,” “contemplates,” or the negative or plural of these words and similar expressions are intended to identify forward-looking statements.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022, as well as in our other filings with the Securities and Exchange Commission. We believe that these risks include, but are not limited to: our ability to manage our growth effectively; the potential breach of our security measures or unauthorized access to our customers’ or their employees’ personal data; the expansion and retention of our direct sales force with qualified and productive persons and the related effects on the growth of our business; the impact on customer expansion and retention if implementation, user experience, customer service, or performance relating to our solutions is not satisfactory; the timing of payments made to employees and taxing authorities relative to the timing of when a customer’s electronic funds transfers are settled to our account; future acquisitions of other companies’ businesses, technologies, or customer portfolios; the continued service of our key executives; our ability to innovate and deliver high-quality, technologically advanced products and services; our ability to attract and retain qualified personnel; the proper operation of our software; our relationships with third parties; the ongoing effects of inflation, supply chain disruptions, labor shortages and other adverse macroeconomic conditions in the market in which we and our customers operate; the impact of an economic downturn or recession in the United States or global economy; and the other risks described in our Annual Report on Form 10-K for the year ended June 30, 2022, as well as in our other filings with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations and assumptions reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. We undertake no obligation to publicly update any forward-looking statement after the date of this report, whether as a result of new information, future developments or otherwise, or to conform these statements to actual results or revised expectations, except as may be required by law.

Non-GAAP Financial Measures

To supplement our financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we present the following non-GAAP financial measures in this press release and on the related teleconference call: adjusted gross profit, adjusted gross profit margin, adjusted operating income, adjusted operating income margin, adjusted sales and marketing expense, adjusted general and administrative expense, adjusted research and development expense, adjusted net income attributable to Paycor HCM, Inc. and adjusted net income attributable to Paycor HCM, Inc. per share. Management believes these non-GAAP measures are useful in evaluating our core operating performance and trends to prepare and approve our annual budget, and to develop short-term and long-term operating plans. Management believes that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance and assists in comparisons with other companies, some of which use similar non-GAAP financial information to supplement their GAAP results. We define (i) adjusted gross profit as gross profit before amortization of intangible assets, stock-based compensation expense, and other certain corporate expenses, in each case that are included in costs of recurring revenues, (ii) adjusted gross profit margin as adjusted gross profit divided by total revenues, (iii) adjusted operating income as loss from operations before amortization of acquired intangible assets and naming rights, stock-based compensation expense, exit cost due to exiting leases of certain facilities and other certain corporate expenses, such as costs related to acquisitions, (iv) adjusted operating income margin as adjusted operating income divided by total revenues, (v) adjusted sales and marketing expense as sales and marketing expenses before amortization of naming rights, stock-based compensation expense and other certain corporate expenses, (vi) adjusted general and administrative expense as general and administrative expenses before amortization of acquired intangible assets, stock-based compensation expense, exit cost due to exiting leases of certain facilities and other certain corporate expenses, (vii) adjusted research and development expense as research and development expenses before stock-based compensation expense and other certain corporate expenses, (viii) adjusted net income attributable to Paycor HCM, Inc. as loss before benefit for income taxes after adjusting for amortization of acquired intangible assets and naming rights, accretion expense associated with the naming rights, stock-based compensation expense, gain or loss on the extinguishment of debt, exit costs due to exiting leases of certain facilities and other certain corporate expenses, such as costs related to acquisitions, all of which are tax effected by applying an adjusted effective income tax rate and (ix) adjusted net income attributable to Paycor HCM, Inc. per share as adjusted net income attributable to Paycor HCM, Inc. divided by adjusted shares outstanding. Adjusted shares outstanding includes potentially dilutive securities excluded from the GAAP dilutive net loss per share calculation.

Other certain corporate expenses presented include one-time costs related to secondary offerings, restructuring costs, professional, consulting and other costs, transaction expenses and other costs, costs associated with becoming a public company and implementation of a new enterprise-resource planning system.

The non-GAAP financial measures presented in this press release and discussed on the related teleconference call are not measures of financial performance under GAAP and should not be considered a substitute for gross profit, gross margin, operating income, operating income margin, sales and marketing expense, general and administrative expense, research and development expense, net income attributable to Paycor HCM, Inc. and diluted net income attributable to Paycor HCM, Inc. per share. Non-GAAP financial measures have limitations as analytical tools, and when assessing our operating performance, you should not consider them in isolation, or as a substitute for analysis of our results as reported under GAAP. The non-GAAP financial measures that we present may not be comparable to similarly titled measures used by other companies. A reconciliation is provided below under “Reconciliations of Non-GAAP Measures to GAAP Measures,” for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP.

Investor Relations:
Rachel White
513-954-7388
[email protected]

Media Relations:
Carly Pennekamp
513-954-7282
[email protected]

Paycor HCM, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands, except share amounts)  

  March 31,
2023
  June 30,
2022
Assets (Unaudited)    
Current assets:      
Cash and cash equivalents $ 82,858     $ 133,041  
Accounts receivable, net   30,506       21,511  
Deferred contract costs   49,982       37,769  
Prepaid expenses   17,256       9,421  
Other current assets   3,533       1,874  
   Current assets before funds held for clients   184,135       203,616  
Funds held for clients   1,258,249       1,715,916  
   Total current assets   1,442,384       1,919,532  
Property and equipment, net   31,404       31,675  
Operating lease right-of-use assets   17,500        
Goodwill   761,425       750,155  
Intangible assets, net   282,956       263,069  
Capitalized software, net   49,819       40,002  
Long-term deferred contract costs   153,519       125,705  
Other long-term assets   3,991       1,179  
   Total assets $ 2,742,998     $ 3,131,317  
Liabilities and Stockholders’ Equity      
Current liabilities:      
Accounts payable $ 20,987     $ 13,945  
Accrued expenses and other current liabilities   18,954       13,907  
Accrued payroll and payroll related expenses   36,515       44,592  
Deferred revenue   12,724       11,742  
   Current liabilities before client fund obligations   89,180       84,186  
Client fund obligations   1,260,057       1,719,047  
   Total current liabilities   1,349,237       1,803,233  
Deferred income taxes   21,848       31,895  
Long-term operating leases   16,644        
Other long-term liabilities   70,005       11,458  
   Total liabilities   1,457,734       1,846,586  
Commitments and contingencies      
Stockholders’ equity:      
Common stock $0.001 par value per share, 500,000,000 shares authorized, 176,440,422 shares outstanding at March 31, 2023 and 174,909,539 shares outstanding at June 30, 2022   176       175  
Treasury stock, at cost, 10,620,260 shares at March 31, 2023 and June 30, 2022   (245,074 )     (245,074 )
Preferred stock, $0.001 par value, 50,000,000 shares authorized, — shares outstanding at March 31, 2023 and June 30, 2022          
Additional paid-in capital   1,991,298       1,926,800  
Accumulated deficit   (459,244 )     (395,389 )
Accumulated other comprehensive loss   (1,892 )     (1,781 )
   Total stockholders’ equity   1,285,264       1,284,731  
   Total liabilities and stockholders’ equity $ 2,742,998     $ 3,131,317  

 Paycor HCM, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except share amounts)

  Three Months Ended   Nine Months Ended
  March 31,   March 31,
    2023       2022       2023       2022  
Revenues:              
Recurring and other revenue $ 150,757     $ 122,189     $ 389,908     $ 317,334  
Interest income on funds held for clients   10,725       408       22,741       1,062  
   Total revenues   161,482       122,597       412,649       318,396  
Cost of revenues   49,323       41,157       138,692       127,850  
   Gross profit   112,159       81,440       273,957       190,546  
Operating expenses:              
Sales and marketing   55,499       41,487       155,607       127,957  
General and administrative   51,033       54,090       151,405       141,963  
Research and development   13,658       9,324       39,935       30,120  
   Total operating expenses   120,190       104,901       346,947       300,040  
   Loss from operations   (8,031 )     (23,461 )     (72,990 )     (109,494 )
Other (expense) income:              
Interest expense   (1,970 )     (101 )     (3,461 )     (448 )
Other   2,003       (12 )     2,514       1,540  
Loss before benefit for income taxes   (7,998 )     (23,574 )     (73,937 )     (108,402 )
Income tax benefit   (658 )     (6,876 )     (10,082 )     (24,204 )
Net loss   (7,340 )     (16,698 )     (63,855 )     (84,198 )
Less: Accretion of redeemable noncontrolling interests                     11,621  
Net loss attributable to Paycor HCM, Inc. $ (7,340 )   $ (16,698 )   $ (63,855 )   $ (95,819 )
Basic and diluted net loss attributable to Paycor HCM, Inc. per share $ (0.04 )   $ (0.10 )   $ (0.36 )   $ (0.56 )
Weighted average common shares outstanding:              
Basic and diluted   176,306,017       174,819,649       175,879,962       171,881,617  
               

Paycor HCM, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)

  Nine Months Ended  
  March 31,  
    2023       2022    
Cash flows from operating activities:        
Net loss $ (63,855 )   $ (84,198 )  
Adjustments to reconcile net loss to net cash provided by operating activities:        
Depreciation   3,571       5,113    
Amortization of intangible assets and software   92,727       95,556    
Amortization of deferred contract costs   33,246       22,330    
Stock-based compensation expense   58,019       55,321    
Deferred tax benefit   (10,287 )     (24,227 )  
Bad debt expense   3,233       1,655    
Loss (gain) on sale of investments   232       (9 )  
Gain on installment sale         (1,359 )  
Loss on foreign currency exchange   381       101    
Loss on lease exit   950       9,055    
Naming rights accretion expense   3,198          
Change in fair value of deferred consideration         (138 )  
Other   (930 )     66    
Changes in assets and liabilities, net of effects from acquisitions:        
Accounts receivable   (12,063 )     (5,391 )  
Prepaid expenses and other assets   (6,510 )     (5,195 )  
Accounts payable   6,229       (160 )  
Accrued liabilities and other   (19,602 )     618    
Deferred revenue   1,119       943    
Deferred contract costs   (73,273 )     (58,450 )  
Net cash provided by operating activities   16,385       11,631    
Cash flows from investing activities:        
Purchases of client funds available-for-sale securities   (365,196 )     (178,362 )  
Proceeds from sale and maturities of client funds available-for-sale securities   259,097       127,603    
Purchase of property and equipment   (3,285 )     (1,861 )  
Proceeds from note receivable on installment sale         3,040    
Acquisition of intangible assets   (18,842 )     (4,640 )  
Acquisition of Talenya Ltd., net of cash acquired   (18,793 )        
Internally developed software costs   (30,600 )     (22,667 )  
Net cash used in investing activities   (177,619 )     (76,887 )  
Cash flows from financing activities:        
Net change in cash and cash equivalents held to satisfy client funds obligations   (453,685 )     1,204,091    
Payment of deferred consideration         (2,752 )  
Proceeds from line-of-credit         3,500    
Repayments of line-of-credit         (52,600 )  
Repayments of debt and capital lease obligations   (211 )        
Proceeds from the issuance of common stock sold in the IPO, net of offering costs and underwriting discount         454,915    
Redemption of Redeemable Series A Preferred Stock (acquisition of noncontrolling interest)         (260,044 )  
Withholding taxes paid related to net share settlements   (2,150 )        
Proceeds from exercise of stock options   345          
Proceeds from employee stock purchase plan   8,285       3,186    
Other financing activities         (395 )  
Net cash (used in) provided by financing activities   (447,416 )     1,349,901    
Impact of foreign exchange on cash and cash equivalents   (15 )     18    
Net change in cash, cash equivalents, restricted cash and short-term investments, and funds held for clients   (608,665 )     1,284,663    
Cash, cash equivalents, restricted cash and short-term investments, and funds held for clients, beginning of period   1,682,923       560,000    
Cash, cash equivalents, restricted cash and short-term investments, and funds held for clients, end of period $ 1,074,258     $ 1,844,663    
Supplemental disclosure of non-cash investing, financing and other cash flow information:        
Capital expenditures in accounts payable $ 2     $ 25    
Cash paid for interest         154    
Reconciliation of cash, cash equivalents, restricted cash and short-term investments, and funds held for clients to the Consolidated Balance Sheets        
Cash and cash equivalents $ 82,858     $ 134,004    
Funds held for clients   991,400       1,710,659    
Total cash, cash equivalents, restricted cash and short-term investments, and funds held for clients $ 1,074,258     $ 1,844,663    

Reconciliations of Non-GAAP Measures to GAAP Measures

Adjusted Gross Profit and Adjusted Gross Profit Margin (Unaudited)

  Three Months Ended   Nine Months Ended
(in thousands) March 31, 2023   March 31, 2022   March 31, 2023   March 31, 2022
Gross Profit* $ 112,159     $ 81,440     $ 273,957     $ 190,546  
Gross Profit Margin   69.5 %     66.4 %     66.4 %     59.8 %
Amortization of intangible assets   1,358       1,433       3,786       18,017  
Stock-based compensation expense   2,440       1,710       6,755       5,205  
Adjusted Gross Profit* $ 115,957     $ 84,583     $ 284,498     $ 213,768  
Adjusted Gross Profit Margin   71.8 %     69.0 %     68.9 %     67.1 %

*    Gross Profit and Adjusted Gross Profit are burdened by depreciation expense of $0.4 million and $0.6 million for the three months ended March 31, 2023 and 2022, respectively, and $1.3 million and $2.0 million for the nine months ended March 31, 2023 and 2022, respectively. Gross Profit and Adjusted Gross Profit are burdened by amortization of capitalized software of $7.2 million and $5.8 million for the three months ended March 31, 2023 and 2022, respectively, and $20.3 million and $16.0 million for the nine months ended March 31, 2023 and 2022, respectively. Gross Profit and Adjusted Gross Profit are burdened by amortization of deferred contract costs of $6.8 million and $4.6 million for the three months ended March 31, 2023 and 2022, respectively, and $18.6 million and $12.2 million for the nine months ended March 31, 2023 and 2022, respectively.

Adjusted Operating Income (Unaudited)

  Three Months Ended   Nine Months Ended
(in thousands) March 31, 2023   March 31, 2022   March 31, 2023   March 31, 2022
Loss from Operations $ (8,031 )   $ (23,461 )   $ (72,990 )   $ (109,494 )
Operating Margin (5.0)%   (19.1)%   (17.7)%   (34.4)%
Amortization of intangible assets   24,467       22,136       72,410       79,548  
Stock-based compensation expense   20,384       16,294       58,019       55,321  
Loss on lease exit*   915       9,055       1,733       9,055  
Corporate adjustments**   1,372       626       7,991       3,871  
Adjusted Operating Income $ 39,107     $ 24,650     $ 67,163     $ 38,301  
Adjusted Operating Income Margin   24.2 %     20.1 %     16.3 %     12.0 %

*    Represents exit costs due to exiting leases of certain facilities.
**    Corporate adjustments for the three and nine months ended March 31, 2023 relate to costs associated with secondary offerings completed in December 2022 (“December 2022 Secondary Offering”) and September 2022 (“September 2022 Secondary Offering”) of $— million and $2.2 million, respectively, professional, consulting, and other costs of $1.0 million and $3.5 million, respectively, and transaction expenses and other costs of $0.4 million and $2.3 million, respectively. Corporate adjustments for the three and nine months ended March 31, 2022 relate to certain restructuring costs of $0.2 million and $0.4 million, respectively, as well as costs associated with becoming a public company, including the implementation of a new enterprise-resource planning system and professional, consulting, and other costs of $0.4 million and $2.5 million, respectively, and costs associated with a secondary offering completed in October 2021 (“October 2021 Secondary Offering”) of $— million and $1.0 million, respectively.

Adjusted Operating Expenses (Unaudited)

  Three Months Ended   Nine Months Ended
(in thousands) March 31, 2023   March 31, 2022   March 31, 2023   March 31, 2022
Sales and Marketing expense $ 55,499     $ 41,487     $ 155,607     $ 127,957  
Amortization of intangible assets   (756 )           (2,823 )      
Stock-based compensation expense   (8,311 )     (7,634 )     (24,408 )     (29,390 )
Corporate adjustments*                     (53 )
Adjusted Sales and Marketing expense $ 46,432     $ 33,853     $ 128,376     $ 98,514  
General and Administrative expense $ 51,033     $ 54,090     $ 151,405     $ 141,963  
Amortization of intangible assets   (22,353 )     (20,703 )     (65,801 )     (61,531 )
Stock-based compensation expense   (7,168 )     (5,846 )     (19,765 )     (16,947 )
Loss on lease exit**   (915 )     (9,055 )     (1,733 )     (9,055 )
Corporate adjustments***   (1,372 )     (626 )     (7,991 )     (3,818 )
Adjusted General and Administrative expense $ 19,225     $ 17,860     $ 56,115     $ 50,612  
Research and Development expense $ 13,658     $ 9,324     $ 39,935     $ 30,120  
Stock-based compensation expense   (2,465 )     (1,104 )     (7,091 )     (3,779 )
Adjusted Research and Development expense $ 11,193     $ 8,220     $ 32,844     $ 26,341  

*    Corporate adjustments for the nine months ended March 31, 2022 relate to costs associated with becoming a public company.
**    Represents exit costs due to exiting leases of certain facilities.        
***    Corporate adjustments for the three and nine months ended March 31, 2023 relate to costs associated with the December 2022 Secondary Offering and the September 2022 Secondary Offering of $— million and $2.2 million, respectively, professional, consulting, and other costs of $1.0 million and $3.5 million, respectively, and transaction expenses and other costs of $0.4 million and $2.3 million, respectively. Corporate adjustments for the three and nine months ended March 31, 2022 relate to certain restructuring costs of $0.2 million and $0.4 million, respectively, as well as costs associated with becoming a public company, including the implementation of a new enterprise-resource planning system and professional, consulting, and other costs of $0.4 million and $2.4 million, respectively, and costs associated with the October 2021 Secondary Offering of $— million and $1.0 million, respectively.

Adjusted Net Income Attributable to Paycor HCM, Inc. and Adjusted Net Income Attributable to Paycor HCM, Inc. Per Share (Unaudited)

  Three Months Ended   Nine Months Ended
(in thousands) March 31, 2023   March 31, 2022   March 31, 2023   March 31, 2022
Net loss before benefit for income taxes $ (7,998 )   $ (23,574 )   $ (73,937 )   $ (108,402 )
Loss on debt amendment                     35  
Amortization of intangible assets   24,467       22,136       72,410       79,548  
Naming rights accretion expense   1,884             3,198        
Gain on installment sale                     (1,359 )
Stock-based compensation expense   20,384       16,294       58,019       55,321  
Loss on lease exit*   915       9,055       1,733       9,055  
Corporate adjustments**   1,372       626       7,991       3,871  
Non-GAAP adjusted income before applicable income taxes   41,024       24,537       69,414       38,069  
Income tax effect on adjustments***   (9,435 )     (5,889 )     (15,965 )     (9,137 )
Adjusted Net Income Attributable to Paycor HCM, Inc. $ 31,589     $ 18,648     $ 53,449     $ 28,932  
               
Adjusted Net Income Attributable to Paycor HCM, Inc. Per Share $ 0.18     $ 0.11     $ 0.30     $ 0.17  
Adjusted shares outstanding****   176,499,160       175,116,109       176,211,488       173,269,703  
               

*    Represents exit costs due to exiting leases of certain facilities.
**    Corporate adjustments for the three and nine months ended March 31, 2023 relate to costs associated with the December 2022 Secondary Offering and the September 2022 Secondary Offering of $— million and $2.2 million, respectively, professional, consulting, and other costs of $1.0 million and $3.5 million, respectively, and transaction expenses and other costs of $0.4 million and $2.3 million, respectively. Corporate adjustments for the three and nine months ended March 31, 2022 relate to certain restructuring costs of $0.2 million and $0.4 million, respectively, as well as costs associated with becoming a public company, including the implementation of a new enterprise-resource planning system and professional, consulting, and other costs of $0.4 million and $2.5 million, respectively, and costs associated with the October 2021 Secondary Offering of $— million and $1.0 million, respectively.
***    Non-GAAP adjusted income before applicable income taxes is tax effected using an adjusted effective income tax rate of 23.0% for the three and nine months ended March 31, 2023, respectively, and 24.0% for the three and nine months ended March 31, 2022, respectively.
****    The adjusted shares outstanding for the three and nine months ended March 31, 2023 are based on the if-converted method and include potentially dilutive securities that are excluded from the U.S. GAAP dilutive net income per share calculation because including them would have an anti-dilutive effect. The adjusted shares outstanding for the three months ended March 31, 2022 are based on the if-converted method and include potentially dilutive securities that are excluded from the U.S. GAAP dilutive net income per share calculation because including them would have an anti-dilutive effect. The adjusted shares outstanding for the nine months ended March 31, 2022 assume the conversion of the Series A Preferred Stock as if it would have occurred on July 1, 2021, based on the if-converted method and include potentially dilutive securities that are excluded from the U.S. GAAP dilutive net income per share calculation because including them would have an anti-dilutive effect.

 

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Clinical Trials Matching Software Market Projected to Reach $832.56 million by 2030 – Exclusive Report by 360iResearch

Published

on

clinical-trials-matching-software-market-projected-to-reach-$832.56-million-by-2030-–-exclusive-report-by-360iresearch

PUNE, India, April 18, 2024 /PRNewswire/ — The report titled “Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use – Global Forecast 2024-2030” is now available on 360iResearch.com’s offering, presents an analysis indicating that the market projected to grow from a size of $342.20 million in 2023 to reach $832.56 million by 2030, at a CAGR of 13.54% over the forecast period.

“The Global Surge in Adoption of Matching Software for Enhanced Participant Enrollment”
Clinical trials matching software stands at the forefront of revolutionizing clinical research by automating the process of identifying and enrolling eligible participants. These platforms offer a streamlined approach to match patient health profiles with trial requirements, accelerating enrollment and supporting the shift toward personalized healthcare using these advanced AI and ML technologies. Although integrating these systems poses challenges due to variations in healthcare IT infrastructure and the imperative for rigorous data security, the potential for market growth is substantial. In the Americas, a robust clinical trials ecosystem thrives; in the European Union, it has unified regulatory standards and extended to emerging regions such as the Middle East, Africa, and the APAC countries; the demand for such innovative solutions is on a steep rise. This demand is fueled by governmental support, the evolving regulatory landscape, and strategic partnerships to embed these solutions within electronic health records, underscoring a global movement toward optimizing clinical trial processes to better cater to specific patient demographics.
Download Sample Report @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
“The Rise of Virtual Trials and Advanced Matching Software”
The healthcare landscape is witnessing a transformative shift toward virtual clinical trials, fueled by technological advancements and the necessity for continuity during the COVID-19 pandemic. This transition supports research amid social distancing measures and introduces significant cost savings by reducing the need for physical infrastructure and in-person interactions. The efficiencies brought by electronic health records (EHR), wearable technologies, and automation streamline the entire process, from patient recruitment to data analysis. Several approaches, endorsed by regulatory bodies such as the FDA, represent a leap forward in making clinical trials more accessible and streamlined, ensuring that more patients can participate in potentially life-saving research without the geographical and logistic constraints of traditional trials.
“Enhancing Clinical Trials through Advanced Analytics, Rigorous Compliance, and Precision-Patient Matching”
Integrating advanced analytics, meticulous compliance monitoring, and precision-patient matching marks a significant advancement toward maximizing efficiency and fostering trial diversity. The software delivers insightful data on trial progress, participant demographics, and enrollment figures, empowering stakeholders to make well-informed decisions and optimize resource distribution to meet trial goals effectively by implementing cutting-edge analytics. The built-in compliance feature ensures trials are conducted in strict adherence to regulatory standards, minimizing risks associated with non-compliance. Furthermore, a robust data management system guarantees the integrity and availability of clinical trial data, which is critical for the seamless operation and real-time analysis of trials. The software includes state-of-the-art patient matching technology, which employs sophisticated algorithms and artificial intelligence to expedite recruitment by accurately identifying candidates who match specific trial requirements. This innovative approach accelerates the recruitment timeline and enhances the diversification of trial participants, paving the way for more inclusive and representative clinical research outcomes.
Request Analyst Support @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
“Medidata by Dassault Systèmes SE at the Forefront of Clinical Trials Matching Software Market with a Strong 11.30% Market Share”
The key players in the Clinical Trials Matching Software Market include International Business Machines Corporation, Science 37, Inc. by eMed, LLC, Medidata by Dassault Systèmes SE, AutoCruitment LLC, Deep 6 AI Inc., and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.
“Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the Clinical Trials Matching Software Market”
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Clinical Trials Matching Software Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive Clinical Trials Matching Software Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.
Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/clinical-trials-matching-software
“Dive into the Clinical Trials Matching Software Market Landscape: Explore 190 Pages of Insights, 286 Tables, and 22 Figures”
PrefaceResearch MethodologyExecutive SummaryMarket OverviewMarket InsightsClinical Trials Matching Software Market, by FunctionalityClinical Trials Matching Software Market, by DeploymentClinical Trials Matching Software Market, by End-UseAmericas Clinical Trials Matching Software MarketAsia-Pacific Clinical Trials Matching Software MarketEurope, Middle East & Africa Clinical Trials Matching Software MarketCompetitive LandscapeCompetitive PortfolioInquire Before Buying @ https://www.360iresearch.com/library/intelligence/clinical-trials-matching-software
Related Reports:
Clinical Trial Support Services Market – Global Forecast 2024-2030Virtual Clinical Trials Market – Global Forecast 2024-2030Clinical Trials Management System Market – Global Forecast 2024-2030About 360iResearch
Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
Contact 360iResearchMr. Ketan Rohom360iResearch Private Limited,Office No. 519, Nyati Empress,Opposite Phoenix Market City,Vimannagar, Pune, Maharashtra,India – 411014.Email: [email protected]: +1-530-264-8485India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.
Logo – https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/clinical-trials-matching-software-market-projected-to-reach-832-56-million-by-2030—exclusive-report-by-360iresearch-302119709.html

Continue Reading

Artificial Intelligence

RepTrak Announces 2024 Global RepTrak® 100 Report

Published

on

reptrak-announces-2024-global-reptrak-100-report

BOSTON, April 18, 2024 /PRNewswire/ — The RepTrak™ Company, the world’s leading reputation data and insights company, released its annual Global RepTrak 100 report. Utilizing its advanced reputation monitoring software, RepTrak gathered data from more than 243,000 survey responses across 14 major economies to rank the world’s 100 most reputable companies. They share that ranking alongside a full analysis of global corporate reputation trends and corresponding public sentiment in the 2024 report.

After two years of consecutive Reputation Score declines, this year’s Score is back up with an increase from 73.2 in 2023 to 73.8 in 2024. It’s a small increase after 2023’s full one-point drop. However, it’s an encouraging sign that companies have begun to recover from reputation falls driven by many challenges: macroeconomic issues, workplace difficulties, product problems, and corporate responsibility skepticism.
“This year’s report underscores a pivotal shift in the corporate landscape, spotlighting the remarkable adaptability and dedication of the Top 100 companies in responding to the dynamic needs of stakeholders,” states RepTrak CEO Mark Sonders. “The companies featured in our report are not just riding the wave of change; they are the ones steering it, proving that the best approach to business is one that embraces evolution and champions progress.”
RepTrak’s report explores how people thought, felt, and acted toward companies over the past year. Findings include notable increases in Conduct and Citizenship efforts, stakeholders’ rising willingness to invest, culturally resonant brand communications, and ESG Scores that soared despite skepticism around the acronym.
To read the full 2024 Global RepTrak 100 report, please visit: www.reptrak.com/globalreptrak
About RepTrak
The RepTrak™ Company is the world’s leading reputation data and insights company. We help companies by organizing and grading a variety of reputational elements, offering a real-world report card on their corporate reputation. Subscribers to the RepTrak program use our predictive insights to protect business value, improve return on investment, and increase their positive impact on society. RepTrak’s pairing of advanced metrics and dedicated reputation advisors offers clients an actionable analysis of their reputation data, aligning business objectives with stakeholder sentiment across different markets and sectors.
Established in 2004, The RepTrak Company owns the world’s largest reputation benchmarking database, gathering over 1 million company ratings per year used by CEOs, boards, and executives in more than 60 countries worldwide. For more information, please visit: www.reptrak.com
Logo – https://mma.prnewswire.com/media/2391550/RepTrak_Logo_Logo.jpg
Photo – https://mma.prnewswire.com/media/2391551/2024_GRT_Spreads__Instagram_Post.jpg

View original content:https://www.prnewswire.co.uk/news-releases/reptrak-announces-2024-global-reptrak-100-report-302121513.html

Continue Reading

Artificial Intelligence

Group-IB takes part in a global operation to cripple Canadian Phishing-as-a-Service provider LabHost

Published

on

group-ib-takes-part-in-a-global-operation-to-cripple-canadian-phishing-as-a-service-provider-labhost

SINGAPORE, April 18, 2024 /PRNewswire/ — Group-IB, a leading cybersecurity company aimed at investigating, preventing, and fight digital crime announced today that it participated in a coordinated global takedown operation against prominent Canadian Phishing-as-a-Service (PhaaS) provider LabHost, which has led to the arrest of 37 suspects across the United Kingdom and around the world by law enforcement agencies. As part of the operation, Group-IB also conducted an extensive analysis of LabHost’s criminal history and infrastructure, including insights into LabHost’s administrative platform and the services it provides to its purported user base which exceeds 2,000 subscribers worldwide, who illegally obtained around 480,000 card numbers, 64,000 pin numbers, and over 1 million passwords from victims used for websites and other online services, according to law enforcement agencies.

“By leveraging our Threat Intelligence and Digital Risk Protection, we are able to identify and monitor phishing attacks and websites like those deployed by LabHost and its subscribers around the world, enabling us to actively alert and protect our customers, and in turn, their customers as well,” said Dmitry Volkov, Chief Executive Officer of Group-IB. “Today’s takedown operation demonstrates the agility and responsiveness of our decentralized Digital Crime Resistance Centers, and how quickly we can provide immediate and local assistance wherever our customers may be.”
First uncovered in late 2021, LabHost emerged as a fully automated Phishing-as-a-Service (PhaaS) platform, streamlining the creation of phishing websites meticulously mirroring the interface and functionality of prominent banking, postal, and financial entities, aimed at intercepting, seizing, and profiting from users’ personal, credit card, and online banking credentials. Users are prompted to select from various “membership plans,” tailored to target businesses and individuals in either the United States and Canada, or globally, akin to mobile subscription models. These plans encompass “standard,” “premium,” and “world membership” tiers, priced between US$179 and US$300 monthly, with options for monthly, quarterly, or annual billing cycles.
For media inquiries, please contact [email protected]
Photo – https://mma.prnewswire.com/media/2391017/Group_IB.jpgPhoto – https://mma.prnewswire.com/media/2391018/Group_IB_2.jpgLogo – https://mma.prnewswire.com/media/1853638/4657466/Group_IB_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/group-ib-takes-part-in-a-global-operation-to-cripple-canadian-phishing-as-a-service-provider-labhost-302121388.html

Continue Reading

Trending